Alumis Inc. ALMS Business Segments — Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alumis Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alumis Inc.'s business segments — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alumis Inc.'s business segments — research and development expense?
- Alumis Inc. (ALMS) reported business segments — research and development expense of $81.54M in Q1 2026.
- How has Alumis Inc.'s business segments — research and development expense changed year-over-year?
- Alumis Inc.'s business segments — research and development expense decreased by 15.6% year-over-year, from $96.62M to $81.54M.
- What is the long-term trend for Alumis Inc.'s business segments — research and development expense?
- Over 2 years (2023 to 2025), Alumis Inc.'s business segments — research and development expense has grown at a 67.4% compound annual growth rate (CAGR), from $137.68M to $386M.
- What does business segments — research and development expense mean?
- The aggregate of all costs incurred in the research and development of new products, including personnel, clinical trials, and overhead. This is a primary indicator of the company's commitment to innovation and the advancement of its clinical pipeline.